SCHEMBL2473575

SCHEMBL2473575

CCOC(=O)c1nn(CC2CC2)c2c1CCC(C)(C)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
LMNA P02545 1/20 0.38
ELANE P08246 2/20 0.34
ACHE P22303 4/20 0.34
OPRM1 P35372 1/20 0.34
CREBBP Q92793 5/20 0.33
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
OGFRL1 Q5TC84 1/20 0.32
BRD4 O60885 4/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31
EP300 Q09472 1/20 0.31
MEN1 O00255 2/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470457 0.87 OPRM1 (0.39) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL2470566 0.84 CREBBP (0.38) CREBBPRXRARXRBRXRGBRD4
SCHEMBL2534722 0.82 ACHE (0.34) ACHEOPRM1CCNA2CDK2CCNA1
SCHEMBL2473191 0.81 CCNA2 (0.38) ELANEACHEOPRM1CCNA2CDK2
SCHEMBL2469013 0.79 CYP19A1 (0.48) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL2474886 0.79 OPRM1 (0.36) ELANEACHEOPRM1CCNA2CDK2
SCHEMBL26108237 0.76 ELANE (0.34) ELANEACHEOPRM1OGFRL1MEN1
SCHEMBL31699353 0.76 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL2472715 0.75 GABRA1 (0.46) ELANECREBBPBRD4EP300MEN1
SCHEMBL3462655 0.75 DRD2 (0.36) ACHEMEN1ALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2370431-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE Almirall S.A. (ES) 2011-10-05 EP disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
WO-2010072352-A1 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2010-07-01 WO disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 PDE4A 177/4885PDE4B 176/4885PDE4C 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.